Propanc Biopharma Receives Orphan Drug Designation from FDA for Treatment of Pancreatic Cancer Jun 26, 2017
A New Audio Interview with James Nathanielsz, Propanc Biopharma Inc.'s Chief Executive Officer, is now at SmallCapVoice.com May 23, 2017
Propanc Biopharma Awaits FDA Response to Orphan Drug Designation Request for Treatment of Pancreatic Cancer, as PRP Progresses to First-In-Human Studies May 16, 2017
Propanc Biopharma Provides Update on Investigational Medicinal Product (IMP) Manufacture of PRP for First-In-Human Studies May 2, 2017
